Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 25, 2026.

Role of Platelet-Derived Microvesicles As Crosstalk Mediators in Atherothrombosis and Future Pharmacology Targets: A Link between Inflammation, Atherosclerosis, and Thrombosis

Lina Badimon, Rosa Suades, Eduardo Fuentes and 2 more

Frontiers in Pharmacology · 2016 · Review

doi:10.3389/fphar.2016.00293

Abstract

Reports in the last decade have suggested that the role of platelets in atherosclerosis and its thrombotic complications may be mediated, in part, by local secretion of platelet-derived microvesicles (pMVs), small cell blebs released during the platelet activation process. MVs are the most abundant cell-derived microvesicle subtype in the circulation. High concentrations of circulating MVs have been reported in patients with atherosclerosis, acute vascular syndromes, and/or diabetes mellitus, suggesting a potential correlation between the quantity of microvesicles and the clinical severity of the atherosclerotic disease. pMVs are considered to be biomarkers of disease but new information indicates that pMVs are also involved in signaling functions. pMVs evoke or promote haemostatic and inflammatory responses, neovascularization, cell survival, and apoptosis, processes involved in the pathophysiology of cardiovascular disease. This review is focused on the complex cross-talk between platelet-derived microvesicles, inflammatory cells and vascular elements and their relevance in the development of the atherosclerotic disease and its clinical outcomes, providing an updated state-of-the art of pMV involvement in atherothrombosis and pMV potential use as therapeutic agent influencing cardiovascular biomedicine in the future.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 25, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Cardiovascular diseases (CVD) result in more than 19 million deaths annually and coronary heart disease (CHD) accounts for the majority of this death toll. In most cases, atherosclerosis and thrombosis associated with unstable plaques are the major cause for cardiovascular events (CVEs) including acute coronary syndromes (ACS) and stroke. Atherosclerosis is a systemic disease that starts early in life, asymptomatically progressing though adulthood, until clinically manifested. Indeed, large numbers of subjects who die suddenly of CHD are apparently healthy and had no previous symptoms. Atherothrombosis is regulated by both genetic and environmental factors (e.g., dyslipidemia, hypertension, smoking, diabetes, and obesity;; ). The development of atherosclerotic lesions result from a complex interplay between circulating factors and various cell types in the vessel wall, which leads to the accumulation of lipids in the subendothelial space and a complex process of chronic inflammation, mainly characterized by endothelial dysfunction, leukocyte infiltration, and platelet activation. Indeed, platelet activation and subsequent platelet aggregation processes play an essential role in the development of atherosclerosis, possibly through a vast amount of molecules released upon platelet activation. Interestingly, increasing evidence support the view that the role of platelets in atherosclerosis and its thrombotic complications may be mediated, in part, by local secretion of molecular effectors embedded or packed into microvesicles from the platelet surface.

Circulating microvesicles (cMVs) may participate in haemostatic and inflammatory responses, neovascularization, cell survival, and apoptosis, processes which are involved in atherothrombosis. Thus, increased levels of cMVs derived from platelets (pMVs), erythrocytes (ErMVs), leukocyte (LMVs), and endothelial cells (eMVs) are associated with individual metabolic abnormalities caused by metabolic syndrome and oxidative stress. ErMVs, LMVs, and eMVs seem to be more abundant in human atherosclerotic plaques than in plasma. High amounts of these plaque MVs result from apoptotic leukocytes within vulnerable plaques. In contrast, MVs of platelet origin are the most abundant in blood. Circulating MVs are found in the plasma of healthy subjects although their relative concentrations are determined by the pathophysiological context. Background levels of circulating pMVs in the absence of disease likely originate from aging platelets in the absence of activation. The local release of MVs from platelets at the site of platelet plug formation indicates a possible role of pMVs in the haemostatic response in vivo. pMV membrane is a composite of the platelet plasma- and granule membranes and have procoagulant properties which lead to thrombin generation. Such procoagulant activity (PCA) relies on the exposure of membrane anionic phospholipids that enable the assembly of coagulation complexes at the MV surface, and on the eventual thrombin formation. Besides the well-known role of platelet-derived MVs in coagulation, thrombosis, and haemostasis, pMVs have been involved in a variety of processes such as wound healing, inflammation, CVD, diabetes, arthritis, tissue regeneration, and cancer.

This review summarizes and highlights the latest findings of the complex cross-talk between platelet-derived microvesicles, inflammatory cells, and vascular elements, and provides novel insight and understanding in the development of the atherosclerotic and thrombotic disease as well as potential clinical application of pMVs in diagnosis and therapy.

Types of Microvesicles

All blood cells are able to release small membrane bound vesicles. Extracellular vesicles (EVs) are a heterogeneous population of membrane-coated microvesicles released by several cell types upon activation or apoptosis, and include plasma membrane-derived microparticles or microvesicles, multivesicular body-derived exosomes, and apoptotic bodies. These different types of EVs vary in size, and in phospholipid, nucleic acid, and protein composition.

Microparticles or microvesicles, which directly originate from the membrane surface, are characterized by phosphatidylserine (PS) exposure and are generally referred to be between 0.1 and 1.0 μm of diameter. MVs, with densities between 1.04 and 1.07 g/mL, are of irregular shape and very heterogeneous in size. In contrast to MVs, exosomes (20–100 nm) are cup-shaped vesicles released from exocytosis of endocytic multivesicular bodies, with a density of 1.10–1.18 g/mL, and the distinction between both types of vesicles is complex due to an overlap in their molecular properties and sizes. Exosomes were first described in platelets, in which the differentiation with MVs is complex because of α-granules, and in general form a more homogenous population than MVs, both by size and molecular content. Thus, multivesicular bodies, the source of exosomes, are also considered to be pre-stages of α-granules, which may then liberate exosomes on fusion with the plasma membrane. However, several α-granule-derived molecules are also present on pMVs. Moreover, the common exosomal marker tetraspanin CD63 is not only enriched in the platelet-derived exosomes, but it is also present on pMVs and, in its turn, many common pMV proteins are detected on subsets of platelet exosomes. Apoptotic bodies, remnants of dead cells in the process of their shrinkage and elimination tend to be larger than MVs, may contain different internal components [e.g., deoxyribonucleic acid (DNA), organelles] and do not present prothrombotic activity despite displaying PS. They present a density of 1.24–1.28 g/mL and their role is still not clear. Apoptotic bodies might be an easier system for cellular clearance themselves due to small size or, alternatively, an active signal to promote cellular clearance of the remaining damaged cells.

Platelet-Derived Microvesicle Release and Clearance

Platelet-derived microvesicles represent about 70–90% of all circulating MV pool and contribute to many biological processes. pMVs are elevated in peripheral blood as a result of chronic platelet activation in various disease states. Exposure of native blood to very high shear rate increases platelet expression of GPIIb/IIIa, rendering the platelet membrane procoagulant and also stimulating pMV formation. Indeed, previous studies with patients with genetic defects have shown that impaired platelet PCA is translated into reduced vesicle formation. Despite the mechanisms by which MVs are formed are not well-known yet, pMVs are specifically shed from the platelet plasma membrane by an exocytic budding process, which involves increases in intracellular calcium, cytoskeleton reorganization and changes in membrane lipid asymmetry, and is triggered by physical stimuli (shear stress, hypoxia), by a variety of specific agonists (in an additive or even synergistic way; ) or by platelet prolonged storage without agonist/stimuli requirement. While most non-physiologic agonists like calcium ionophore are the most potent inducers of MVs, the order of potency of physiologic agonists is C5b-9 membrane attack complex >thrombin plus collagen >thrombin >collagen >adenosine diphosphate >epinephrine. Other platelet stimuli are proinflammatory mediators [like lipopolysaccharide, cytokines, and soluble CD40 ligand], PAR agonists, thrombin receptor activating peptide, and prolyl gallate, among others. Regarding ADP, the P2Y12 receptor contributes to pMV formation from activated platelet surfaces without any significant involvement of the P2Y1 receptor.

Clearance of pMVs remains unknown. In contrast to platelets that have a life span of about 10 days, pMV half-life is about 30 min in mice, or even less than 10 min in rabbits. In other circumstances, such as insertion of material test segments to a shunt in canines, pMV clearance is delayed to a 3–24 h period following removal of test segment from the shunt. Recently, aphaeresis-derived pMVs were shown to circulate for more than 5 h, increasing the discrepancy in pMV turnover, which may rely on distinct fate signals due to secretion process. Indeed, levels of pMVs might reflect the balance between dynamic mechanisms for release and clearance.

Platelet-Derived Microvesicles

Platelet-derived microvesicles retain certain parental cell characteristics, such as surface receptors, although their content depends on platelet stimuli, giving differences in their phenotype. pMV protein content is highly dependent on the type of physiological agonists involved in platelet stimulation. MVs were shown to differ in content between human samples and between MV size classes. Regarding phospholipid MV content, the relative abundance of lyso-phosphatidylcholines among other phospholipid classes (phosphatidylcholines, lyso-phosphatidylethanolamines, PSs, phosphatidylinositols, sphingomyelins, and diacyl- and plasme(a)nyl-phosphatidylethanolamines) was found to be significantly higher in blood MVs than platelets and platelet-derived MVs. In terms of protein composition, pMVs from activated platelets are highly enriched in α-granule-derived factor Va and Xa and thus possess procoagulant properties. Despite their heterogeneity a high percentage of pMVs express surface activation markers such as glycoprotein (GP)-Ibα (CD42b), P-selectin (CD62P), β3-integrin (GPIIIa, CD61), αIIb-integrin (GPIIb, CD41), lysosomal-associated membrane protein-3 (LAMP3, CD63), and thrombospondin-1 (TSP-1). However, healthy individuals may also have CD41+/CD61+/PS+-MVs derived from megakaryocytes instead of activated platelets. Megakaryocyte-derived MVs differ from pMVs in that they do not express granule fusion markers (CD62P-, LAMP-1-) and only contain full-length filamin A. pMVs carry as well other platelet proteins such as platelet activating factor (PAF), β-amyloid precursor, anticoagulant protein C/S, complement C56b-9, and the chemokines CXCR4, CXCL4, CXCL7, and CCL5, which may exert potent biological effects in recipient cells of the circulation. Indeed, pMVs were able to transfer fully operational surface receptors, such as CSCR4 and CD41, onto the recipient cells. pMVs thereby might modulate platelet, leukocyte, and vascular endothelial cells (EC) function, by modulating monocyte-EC interactions and inducing chemotaxis. Because pMVs circulate in the blood flow, they could serve as shuttle modules and signaling transducers not only to neighboring cells (local environment) but also to cells at relative distance from their cell or site of origin, triggering cell activation, phenotypic modification, and reprogrammation of cell function, complementing the well-known processes of intercellular communication. How MVs are selectively released and targeted to exert their various pathophysiological functions remains unknown.

Platelet-Derived Microvesicles and Cardiovascular Disease

Plasma levels of circulating MVs are known to increase with the presence of cardiovascular risk factors [hypercholesterolemia, obesity, hypertension, diabetes mellitus (DM;; ), metabolic syndrome, sleep apnea, and progression of atherosclerosis]. Within DM, type-1 DM patients had twice tissue factor (TF)-positive pMVs than type-2 DM patients. Likewise, elevated pMVs are associated with the 10-year CVD risk score and with age in healthy men. Indeed, total number of pMVs was significantly greater in women than men in a population of healthy individuals. During past decades, the involvement and importance of the immune system and inflammation in the initiation and progression of atherothrombosis has become clear, also contributing to CVD risk. Raised levels of circulating pMVs have been detected in young women with polycystic ovary syndrome, in patients with rheumatoid arthritis in which pMVs express CLEC-2 and in patients with antiphospholipid antibodies in which pMVs correlate with anti-β2-GP. Additionally, elevated levels of circulating pMVs contribute to the increase PCA in patients with oral cancer.

High concentrations of circulating pMV (ranging from ∼3,000–11,000/μL) have been reported in patients with CHD including ACS. In addition, circulating pMVs have been reported to reflect the size of myocardium at risk in patients with ST-elevation myocardial infarction and correlated with the presence of atherothrombotic lesions in carotid plaques, intracranial atherosclerotic lesions, early stage of coronary artery calcification in menopausal women, cerebrovascular disease and peripheral arterial disease. Stenting in stable coronary atherosclerotic lesions is associated with a substantial release of pMVs. Interestingly, the link with increased circulating pMV levels is more consistent with coronary artery disease patients than in those with chronic kidney disease. Indeed, overproduction of pMVs and platelet activation with suppressed aggregation may be even implicated in the pathogenesis of coagulation abnormalities in children with congenital heart disease. Recently, pMVs have been point out as biomarker of the vaso-occlusive phenotype-related severity in sickle cell anemia. Furthermore, pMVs seem to be involved in the development of disseminated intravascular coagulopathy in critically ill patients but are not related to hospital mortality, while pMV/platelet ratio is independently associated to hospital mortality. Finally, total pMVs were lower while activated platelet-derived MVs (P-Sel+) were higher in preeclampsia than in healthy women, being involved in the hypercoagulable intravascular reaction during pregnancies complicated by preeclampsia. Therefore, pMV may reflect the severity of the endothelial injury and platelet activation during thrombotic events.

Acquiring knowledge about the role of pMVs in CVD might also have implications for treatment. Caution must be taken when considering cMVs as pathological markers, since medical therapy with pharmacological agents can affect MV release during disease progression. Thus, pMVs are susceptible targets for pharmacological modulation and offer new options for therapies specifically focused on lowering MV levels. For instance, anti-platelets drugs such as GPIIb/IIIa inhibitors, acetilsalicilic acid, and clopidogrel, and the anti-diabetic drug ticlopidine have shown to reduce pMVs. In patients under antithrombotic treatment, pMVs exposing CD62P or CD142 are still elevated 6 months after initiation of the therapy, possibly due to the fact that low-dose of acetilsalicilic acid might not be strong enough to suppress shedding of pMVs into the microcirculation. Our group has reported that aspirin intake in diabetic patients has no effect on pMVs. However, statins as the cornerstone drug therapy for lipid-lowering decrease pMVs in patients with different cardiovascular risk factors. Thus, simvastatin and pravastatin decreased pMVs in patients with hypertension and type-2 diabetes. Similarly, atorvastatin reduces thrombin generation and expression of TF, GPIIIa, and CD62P on pMVs in patients with peripheral vascular disease and with type-1 diabetes and dyslipidemia. In a recent study aimed to evaluate the effects of lipid-lowering treatment on cMV generation in patients in primary prevention of atherosclerosis, we have demonstrated that, in hypercholesterolemic patients, statin treatment reduces not only the number of pMVs but markers of activated platelets, activated inflammatory cells and TF with respect to untreated subjects even when LDL levels were similar. In agreement, stroke patients with hyperlipidemia presented a significantly lower percentage of pMVs compared to control subjects, not only due to lipid-lowering but also because of a significant role in reduction of platelet activation and reactivity. Hence, in view of all these data statins may exert beneficial effects by inhibiting microvesicle generation and the triggering of MV-dependent mechanisms. Other cardioprotective agents that have an impact on pMV levels include calcium channel blockers, antioxidants such as vitamin C, and PPAR-pan agonists like bezafibrate. As several therapeutic drugs seem to influence the levels and composition of pMVs, the lowering of pMV load in the circulation might prove, at least in part, to be a novel therapeutic strategy for treatment. Nevertheless, whether the beneficial effect of a pharmacological approach is associated to pMV reduction and to a clinical improvement needs to be fully demonstrated.

In addition to pharmacological modulation, the therapeutic potential of progenitor cell-derived microvesicles is promising since they are naturally occurring, efficient, therapeutic delivery vehicle that might be used to deliver drugs to specific targets. Furthermore, the therapeutic potential of MVs has also been pointed out by the use of synthetic MVs, mimicking natural ones. MVs could have a broad potential in several conditions from inflammation to MI. Further characterization of the biological effects of these MVs is warranted.

Platelet-Derived Microvesicles in Atheroinflammation and Atherothrombosis

Platelets are not only key mediators of thrombosis but also of inflammation by directly interacting with cells of the immune system. Reports in the last decade have described the secretion by platelets of proinflammatory molecules that exacerbate the inflammatory response in atherosclerotic lesions, during the initial injury to the endothelium as well as in the later stages when the atherosclerotic plaque is destabilized. In addition to their pivotal role in CVD event presentation, platelet-derived MVs participate in inflammatory responses because they carry immune complexes, which are highly proinflammatory. High-shear-stress-induced pMVs in a cone-plate viscometer device in vitro enhance expression of inflammatory cytokines either in ECs or in the human monocytic THP1-cell line. Of note, pMVs may have a role in initial stages of atherosclerotic process, as they can facilitate cell-to-cell communication and adhesion processes between blood and vessel wall. pMVs could also play part in atherogenesis by enhancing proliferation of vascular smooth muscle cells (SMCs) as well as EC and chemotaxis and proliferation of hematopoietic cells. These results clearly suggest that pMVs contribute to atherosclerosis development and to vascular damage occurring in inflammatory disorders. To this respect, have described that blood pMV levels positively associate with abnormal carotid IMT and other risk factors in obesity suggesting a critical role of enhanced platelet reactivity in atherosclerotic wall alteration. In addition to pMVs, circulating lymphocyte-derived CD45+/CD3+-MVs have recently been shown to be biomarkers of asymptomatic subclinical lipid-rich atherosclerotic plaques in patients with familial hypercholesterolemia, and CD11b+-LMV of unstable plaques in asymptomatic patients with high-grade carotid stenosis. Indeed, CD45+/CD3+-lymphocyte-derived MVs were found increased in individuals at high cardiovascular risk (HCVR) who were about to develop a major CVE.

In a similar fashion, levels of pMVs were significantly higher in patients with intermediate coronary lesions compared to subjects with normal coronary arteries. Progression of early atherosclerotic lesions to advanced plaques and their thrombotic complications are consequence of complex interactions between blood cells and arterial vessel wall components. Erosion, fissure, or rupture of the atherosclerotic plaques are triggering events in ACS, being platelets a key player in these atherothrombotic processes. We have found that HCVR patients have significantly high shedding of cMVs carrying epitopes of platelet activation and directly associate to lipid-rich subclinical atherosclerotic burden. Besides, these prothrombotic pMVs have demonstrated an incremental prognostic value beyond the classical risk factor model for the prediction of cardiovascular risk, indicating that the state of activation of platelets in the blood-vascular interface may increase the release of pMVs that become markers of the high atherothrombotic risk. Blood thrombogenicity can be partially explained by the fact that TF is not only present in the subendothelium, but also in the circulation. TF is associated with monocytes, platelets, and even microvesicles, the latter represent an important source of the so-called blood-borne TF. We have also detected higher numbers of TF-positive MVs derived from platelets in HCVR patients; thus, pMV-associated TF might contribute to atherothrombosis. In the same line, our group has reported that clustering the information provided by TF+-pMVs, eMVs, and LMVs might predict CVEs in high-risk patients following a Mediterranean diet supplemented with nuts.

Besides a potential relevance of MVs and pMVs as markers of subclinical atherosclerosis with a critical importance in reclassification of asymptomatic subjects, the follow-up study performed by in patients with a first ACS points to the fact that high pMV levels at discharge may also be an independent predictor for secondary thrombotic events and poorer clinical outcomes at 1 year. This study stresses the usefulness of pMV levels to differentiate patients who develop secondary atherothrombotic events from patients who develop a stable phenotype after a first ACS.

As pre- and analytical methodological procedures (;; out of the scope of this review) are still under assessment, care should be taken when expanding findings to prospective clinical studies. Prior to large-scaling, it would be desirable a complete international standardization of cMVs analysis.

Further to their potential as biomarkers of cell activation, increasing evidence support the concept that pMVs are causal inducers of atherosclerosis progression and thrombosis. MVs from human atherosclerotic plaques are highly abundant and more thrombogenic than plasma MVs, with differences between LMVs and pMVs. using a model of venous thrombosis, provided evidence that thrombus weight correlated negatively with LMVs and positively with pMVs. Besides, levels of pMVs have been found to be higher in culprit coronary arteries than in peripheral arteries of STEMI patients. In this microenvironment, pMVs released by activated platelets may provide a new prothrombotic interface for fibrin formation between the circulating blood and the growing thrombus, since they are able to interact with fibrin. Thus, it has been proposed that pMVs might play a key role in vivo causing thrombotic events, even without the direct involvement of platelets. The response to this hypothesis was provided by demonstrating that pMVs, beyond being biomarkers of cell activation, have functional effects on cardiovascular atherothrombotic disease because they enhance platelet and fibrin deposition on atherosclerotic arterial wall. This proof of principle study was performed perfusing atherosclerotic vessel wall with blood with/without exogenously added pMVs and showed that high pMVs concentration was able to induce more platelet and fibrin deposition (Figure 1). We have also found a decrease of pMVs with surface markers of adhesion and activation in the post-thrombus blood after perfusing the exposed thrombogenic surfaces and in STEMI-patients. Therefore, our data reinforce pMVs in blood promotes platelet adhesion due to a high tendency to adhere, as previously reported and support their clear implication in the atherothrombotic process. Altogether, this growing body of evidence support the view that pMV dissemination and exposure of their procoagulant membrane to the extracellular matrix at the site of endothelial injury or onto the forming fibrin may serve as an adhesion surface on adhered platelets and within the thrombus to enable thrombin generation and to further support recruitment of platelets and leukocytes stimulating platelet aggregation.

Molecular and Cellular Mechanisms Relating pMVs with Atherosclerosis Progression and Thrombus Formation

As described above, pMVs are considered to be both biomarkers and effectors of cell signaling. Importantly, circulating MVs can mediate communication between vascular cells because they allow membrane interactions between cells at distance. Elucidation of the molecular mechanisms by which MVs might evoke and promote vascular inflammation, atherosclerosis plaque progression, and thrombus formation (Figure 2) is crucial for improving our understanding of their role in health and disease. Hereby, we present a compilation of functional studies investigating the underlying pMV-driven molecular processes in atherothrombosis by using either in vitro, in vivo, or ex vivo models (Table 1):

Platelet-Derived Microvesicles and Endothelial Dysfunction

Platelet-derived microvesicles pMVs interact with activated ECs and recruit activated platelets to injured subendothelium. T lymphocytes are recruited in the atherosclerotic lesion and an immunomodulatory role of pMVs on T cells has been recently described. pMVs carry a concentrated CD40L signal, induce polymorphonuclear leukocyte-damage of human pulmonary microvascular ECs and may affect the development of transfusion-related acute lung injury. Since MVs from platelets contain active executive caspase-3, they have also been involved in apoptosis.

Platelet-Derived Microvesicles and Proinflammatory Activity

Platelet-derived microvesicle seem to be proinflammatory mainly through activating ECs and enhancing cytokine responses. Thus,, based on in vitro cell culture studies, described that pMVs activate ECs and monocytes, which results in increased adherence between both cell types. The effect of pMVs may relay in their content of unmetabolized AA and involve activation of PKC. Part of the proinflammatory and proatherogenic potential of pMVs has been related to their capacity to act as a transcellular delivery system for chemokines such as RANTES (CCL5) on activated vascular endothelium (outside-in signaling mechanism involving GP-IIb/IIIa and junctional adhesion molecule-A) triggering monocyte adhesion into early atherosclerotic lesions. Thus, MVs from stimulated platelets that are able to activate monocytes through RANTES, in turn facilitate monocyte migration, tissue recruitment and differentiation toward macrophage.

In addition, pMVs promote expression of Von Willebrand factor (vWF) at the EC surface (involving anionic phospholipids, lactadherin, and GPIIb/IIIa) and the subsequent platelet/EC interaction under flow. pMVs also induce the expression of cyclooxygenase (COX)-2, but not COX-1. Moreover, upon platelet activation and in response to lipopolysaccharide stimulation (TLR4/JNK/Akt pathway; ), a portion of IL-1β is shed in its mature form in pMVs and stimulates the adhesiveness of human ECs to leukocytes.

Other studies have shown that pMVs are also carriers of PAF. Its presence in pMVs plays an important role in cell-to-cell interactions, as observed in models of acute and chronic inflammation. In this context, PAF production may be of great importance in coronary atherothrombosis and in the inflammatory response elicited during intracoronary injury induced by angioplasty.

Interestingly, pMVs can also affect leukocyte aggregation and recruitment by direct interactions mediated by P-Selectin/PSGL-1-dependent interactions under flow conditions, especially in diseases where the concentration of the particles is elevated, as well as Mac-1. In this regard, pMV binding to neutrophils can also increase neutrophil aggregation and phagocytic activity and pMVs trigger monocytic cell aggregation and release of procoagulant TF-expressing MVs in vitro. In addition to pMV-mechanisms leading to inflammatory response, MVs released from thrombin-stimulated platelets to the extracellular space might contain mitochondria, which are able to interact with neutrophils triggering their adhesion to the endothelial wall. Additionally, pMVs from thrombin-activated platelets expressed CD40L and enhanced monocyte-derived dendritic cell maturation leading to the activation of T cells.

However, there are also conflicting reports in the scientific literature. pMVs inhibit IL-17 and IFN-γ production by regulatory T cells through P-selectin. pMVs also show inhibitory properties on macrophage and DC differentiation, emphasizing the concept of selective packaging of MV cargo dependent on platelet stimulus and the need to advance pMV characterization in future studies. Thus, pMVs actively take part in the immune response regulation at sites of vascular inflammation, where they are known to adhere and interact with leukocytes, promoting the healing process.

Furthermore, several lines of recent evidence support the concept that pMVs contain several miRNAs which may facilitate the communication between platelets with inflammatory cells. For further details on this issue, please refer to review from. All these crosstalk interactions are important for the propagation of inflammation at the site of vascular injury, as well as for sustaining thrombus growth.

Finally, pMVs contain transcription factors, such as PPARγ, derived from parent cells. And proteomic analysis has led to the discovery of three other transcription factors in pMVs: RuvB-like 2, STAT3, and STAT5A. pMV signaling induces differential expression of inflammation-relevant genes in monocytes, which represents a novel link between homeostasis and inflammation. Besides, pMVs formed by aging platelets in an apoptotic-like process promote differentiation of monocytes to a resident CD14+/CD36+/CD68+-macrophage phenotype. These macrophage-like cells release metalloproteinases and H2O2 that contribute to plaque destabilization and eventual rupture, a clinically precipitating event in atherosclerotic disease. Moreover, pMVs have shown to inhibit apoptosis of polymorphonuclear leukocytes. Therefore, specific bioactive pMV cargoes of miRNAs as well as of lipids and proteins might offer novel pharmacological targets for atherothrombosis therapy applicable in each stage of disease.

Platelet-Derived Microvesicles and Procoagulant Activity

Although pMVs can express both procoagulant and anticoagulant proteins, a key feature of pMV is their procoagulant potential. High shear-stress rates and immobilized vWF on the luminal surface of an obstructing atherosclerotic plaque can trigger the generation of procoagulant MV via platelet GPIbα-vWF interactions. Through membrane transverse migration and surface exposure of anionic phospholipids including PS, platelets release PS+-pMV that possess high affinity binding sites for activated coagulation factors such as factor IXa, Va, Xa, and VIII and provides a catalytic environment optimal for subsequent thrombin formation., by comparing procoagulant properties of A23187-calcium ionophore-activated platelets and pMVs using several in vitro models of haemostasis, have provided evidence that pMV surface is approximately 50- to 100-fold more procoagulant than activated platelet surface. Low levels of procoagulant PS-positive pMVs are associated with impaired clot formation in trauma patients and may play an important role in trauma-associated coagulopathy.

Another molecular property that conveys PCA to pMV is functional TF. As stated, the cellular origin of blood-borne TF is unresolved. LMV seem to display the most relevant amount of TF, the most important initiator of intravascular thrombin and fibrin formation. Although TF cell origin is still controversial, today is generally accepted that platelets carry and transfer TF and also possess mechanisms to internalize TF-rich MVs, and that platelet-associated TF enhances platelet reactivity and thrombin generation with flowing blood. Increased TF-positive procoagulant MVs are present in the circulating blood of patients under pathological conditions and are taken up by platelets inducing aggregation in the presence of factor VII. According to, pMV transfer TF to monocytes but not to neutrophils. In fact, in vivo appearance of TF-bearing pMV on leukocytes in pericardial blood during cardiac surgery has been reported. Other studies, however, describe a lack of TF in pMV because it is not packed in the platelet-derived MV during platelet activation. This latter finding arise the concept that MV derived from monocytes and platelets exhibit unique PCA and differentially modulate clot formation, structure and stability. According to this hypothesis, monocyte-derived MV would initiate the extrinsic pathway whereas pMV would augment thrombin generation and promote clot propagation following TF- or contact-initiated clotting. Further studies on in vivo thrombosis models are necessary to investigate the contribution of MVs from different parent cells to the thrombotic process.

Platelet-Derived Microvesicles and Neovascularization in Atherosclerotic Plaques

A key factor in the evolution of subclinical atherosclerosis to an ischemic event is the increased vulnerability of atherosclerotic plaques. It is not known why some of the existing plaques in the arterial tree rupture and trigger thrombotic complications while some others do not. Human coronary plaques associated to ACS show the highest accumulation of neovessels. Increasing evidence shows that high density of neovessels in coronary atherosclerotic lesions is associated with hemorrhagic leaky vessels, unstable plaques, and high rate of thrombotic episodes. During plaque development pro-angiogenic pathways seem to be re-activated leading to formation of immature blood vessels prone to rupture. Infiltration of microvessels into the media, intima, and plaques, originates predominantly from proliferating vasa vasorum although recent work has also signaled toward bone marrow-derived circulating endothelial progenitor cells (EPC; ). pMVs have shown to promote angiogenesis in a number of studies. In vitro cell culture studies provide evidence that pMV promote cell proliferation and survival, migration, and tube formation in human umbilical vein EC via GPCR and kinase signaling pathways. Similarly, pMV augment the adhesion and neovascularization capacities of circulating angiogenic cells obtained from atherosclerotic patients through a RANTES-mediated mechanism. pMVs induce sprouting both in vivo and in vitro and influence the angiogenic activity of EPC. pMV-induced invasion of ECs through a layer of matrigel was mediated by vascular endothelial growth factor, heparanase, and platelet-derived growth factor, but not by basic fibroblast growth factor. Both Dok-2 and CD49f proteins participate in the mechanisms that regulate angiogenesis and, interestingly, are shown to be again differentially regulated in pMV depending on the platelet stimulus. These data are in line with the studies that show a differential localization of angiogenic cytokines in different platelet granules and that the release of angiogenic regulatory proteins is modulated by physiological processes, indicating by which mechanism operate the pro-angiogenic effect of pMVs. In a stroke model, a local delivery of pMV to the lateral ventricles induces angiogenesis, neurogenesis, and neuroprotection and reduces behavioral deficits after brain ischemia.

Thus, in pathological states such as subclinical advanced atherosclerosis, pMV shed from the circulating platelets may reach adequate concentrations and that elevated levels of pMV could contribute to plaque development and instability. In a distinct scenario, pMVs could also collaborate with the remote conditioning protective effect against ischemic-reperfusion injury in a model of cerebral infarction, likely by exerting similar angiogenic properties. Indeed, ischemia-reperfusion preconditioning induces an increase in pMVs, which confer at least part of the remote protective effect against cardiac ischemic-reperfusion injury.

Exosomes

Within EVs platelet-derived exosomes, first described by, have received increasing attention due to their potential role as mediators of cell-to-cell communication. The presence of exosomes containing miRNAs in circulating blood, mainly derived from platelets, has emerged as a potential source of biomarkers of CVD. Additionally, they have been implicated in vascular and heart functions. Ago-miR-223 is delivered to EC via microvesicles from activated platelets and platelet-derived exosomes reduce ICAM-1 expression decreasing monocyte adhesion and induce EC apoptosis. Thrombin-stimulated platelet-derived exosomes, enriched in miR-223, miR-339, and miR-21, inhibit PDGFR β expression in SMCs. Moreover, exosomes may serve as effectors by which damaged heart communicate for cardiac injury repair in the setting of MI. It is not clear so far whether the intervention on exosome secretion processes during disease would have therapeutic effects. However, in the next upcoming years, study of exosomes molecular insights may help not only to detect novel biomarkers of disease but also to provide potential new therapeutic approaches for atherothrombotic cardiovascular disease.

Conclusion and Perspectives

Platelet-derived microvesicles may not only act as a biomarkers of cell activation but also as important functional effectors that linking inflammation, hypercoagulability and neovascularization may contribute to the exacerbation of atherosclerotic lesion growth and to ongoing thrombosis. Thus, pMVs are emerging as novel and specific pharmacological targets to manage atherothrombosis and, additionally as potential therapeutic tools for drug delivery, cardioprotection, and regenerative and personalized medicine. Although our understanding of pMVs has considerably been expanded in the last decade, we are far from completely understanding platelet microvesicle biology. In the upcoming years, platelets and platelet-derived MV research will likely advance and take a leading position in tackling down CVD.

Further studies are required to improve our knowledge on the mechanisms underlying generation of circulating pMV, from the characterization of the specific phenotype of released pMVs by distinct stimuli and pathophysiological context, to the identification of the complete composition and its influence on other cells, and to the disentangling of molecular and signaling processes involving pMVs as functional effectors in atherosclerosis and atherothrombosis.

Author Contributions

LB, IP, and TP conceived and coordinated the design of the review. LB, RS, and EF wrote the paper. RS and EF made figures; LB and RS edited the paper. All authors wrote part of the manuscript, provided critical comments, revised the manuscript and approved the final version of the manuscript.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer JZ and handling Editor declared their shared affiliation, and the handling Editor states that the process nevertheless met the standards of a fair and objective review.

References 215

  1. 1.

    Aatonen M. Gronholm M. Siljander P. R. (2012 ). Platelet-derived microvesicles: multitalented participants in intercellular communication. Semin. Thromb. Hemost. 38 102–113.

    Not in our library10.1055/s-0031-1300956

  2. 2.

    Aatonen M. T. Ohman T. Nyman T. A. Laitinen S. Gronholm M. Siljander P. R. (2014 ). Isolation and characterization of platelet-derived extracellular vesicles. J. Extracell. Vesicles 3 24692

    Not in our library10.3402/jev.v3.24692

  3. 3.

    Abdel-Monem H. Dasgupta S. K. Le A. Prakasam A. Thiagarajan P. (2010 ). Phagocytosis of platelet microvesicles and beta2- glycoprotein I. Thromb. Haemost. 104 335–341.

    Not in our library10.1160/th09-12-0849

  4. 4.

    Aleman M. M. Gardiner C. Harrison P. Wolberg A. S. (2011 ). Differential contributions of monocyte- and platelet-derived microparticles towards thrombin generation and fibrin formation and stability. J. Thromb. Haemost. 9 2251–2261.

    Not in our library10.1111/j.1538-7836.2011.04488.x

  5. 5.

    Ando M. Iwata A. Ozeki Y. Tsuchiya K. Akiba T. Nihei H. (2002 ). Circulating platelet-derived microparticles with procoagulant activity may be a potential cause of thrombosis in uremic patients. Kidney Int. 62 1757–1763.

    Not in our library10.1046/j.1523-1755.2002.00627.x

  6. 6.

    Ayers L. Nieuwland R. Kohler M. Kraenkel N. Ferry B. Leeson P. (2015 ). Dynamic microvesicle release and clearance within the cardiovascular system: triggers and mechanisms. Clin. Sci. (Lond.) 129 915–931.

    Not in our library10.1042/cs20140623

  7. 7.

    Azevedo L. C. Pedro M. A. Laurindo F. R. (2007 ). Circulating microparticles as therapeutic targets in cardiovascular diseases. Recent Pat. Cardiovasc. Drug Discov. 2 41–51.

    Not in our library10.2174/157489007779606121

  8. 8.

    Badimon L. Vilahur G. (2014 ). Thrombosis formation on atherosclerotic lesions and plaque rupture. J. Intern. Med. 276 618–632.

    Not in our library10.1111/joim.12296

  9. 9.

    Baj-Krzyworzeka M. Majka M. Pratico D. Ratajczak J. Vilaire G. Kijowski J. (2002 ). Platelet-derived microparticles stimulate proliferation, survival, adhesion, and chemotaxis of hematopoietic cells. Exp. Hematol. 30 450–459.

    Not in our library10.1016/s0301-472x(02)00791-9

  10. 10.

    Barry O. P. Kazanietz M. G. Pratico D. FitzGerald G. A. (1999 ). Arachidonic acid in platelet microparticles up-regulates cyclooxygenase-2-dependent prostaglandin formation via a protein kinase C/mitogen-activated protein kinase-dependent pathway. J. Biol. Chem. 274 7545–7556.

    Not in our library10.1074/jbc.274.11.7545

  11. 11.

    Barry O. P. Pratico D. Lawson J. A. FitzGerald G. A. (1997 ). Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles. J. Clin. Invest. 99 2118–2127.

    Not in our library10.1172/jci119385

  12. 12.

    Barry O. P. Pratico D. Savani R. C. FitzGerald G. A. (1998 ). Modulation of monocyte-endothelial cell interactions by platelet microparticles. J. Clin. Invest. 102 136–144.

    Not in our library10.1172/jci2592

  13. 13.

    Bastos-Amador P. Royo F. Gonzalez E. Conde-Vancells J. Palomo-Diez L. Borras F. E. (2012 ). Proteomic analysis of microvesicles from plasma of healthy donors reveals high individual variability. J. Proteomics 75 3574–3584.

    Not in our library10.1016/j.jprot.2012.03.054

  14. 14.

    Battinelli E. M. Markens B. A. Italiano J. E. Jr. (2011 ). Release of angiogenesis regulatory proteins from plateletalpha granules: modulation of physiologic and pathologic angiogenesis. Blood 118 1359–1369.

    Not in our library10.1182/blood-2011-02-334524

  15. 15.

    Berckmans R. J. Nieuwland R. Boing A. N. Romijn F. P. Hack C. E. Sturk A. (2001 ). Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb. Haemost. 85 639–646.

    Not in our library

  16. 16.

    Biasucci L. M. Porto I. Di Vito L. De Maria G. L. Leone A. M. Tinelli G. (2012 ). Differences in microparticle release in patients with acute coronary syndrome and stable angina. Circ. J. 76 2174–2182.

    Not in our library10.1253/circj.cj-12-0068

  17. 17.

    Biro E. Akkerman J. W. Hoek F. J. Gorter G. Pronk L. M. Sturk A. (2005 ). The phospholipid composition and cholesterol content of platelet-derived microparticles: a comparison with platelet membrane fractions. J. Thromb. Haemost. 3 2754–2763.

    Not in our library10.1111/j.1538-7836.2005.01646.x

  18. 18.

    Boilard E. Nigrovic P. A. Larabee K. Watts G. F. Coblyn J. S. Weinblatt M. E. (2010 ). Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science 327 580–583.

    Not in our library10.1126/science.1181928

  19. 19.

    Boing A. N. Hau C. M. Sturk A. Nieuwland R. (2008 ). Platelet microparticles contain active caspase 3. Platelets 19 96–103.

    Not in our library10.1080/09537100701777295

  20. 20.

    Boudreau L. H. Duchez A. C. Cloutier N. Soulet D. Martin N. Bollinger J. (2014 ). Platelets release mitochondria serving as substrate for bactericidal group IIA-secreted phospholipase A2 to promote inflammation. Blood 124 2173–2183.

    Not in our library10.1182/blood-2014-05-573543

  21. 21.

    Brill A. Dashevsky O. Rivo J. Gozal Y. Varon D. (2005 ). Platelet-derived microparticles induce angiogenesis and stimulate post-ischemic revascularization. Cardiovasc. Res. 67 30–38.

    Not in our library10.1016/j.cardiores.2005.04.007

  22. 22.

    Brown G. T. McIntyre T. M. (2011 ). Lipopolysaccharide signaling without a nucleus: kinase cascades stimulate platelet shedding of proinflammatory IL-1beta-rich microparticles. J. Immunol. 186 5489–5496.

    Not in our library10.4049/jimmunol.1001623

  23. 23.

    Brunetti M. Martelli N. Manarini S. Mascetra N. Musiani P. Cerletti C. (2000 ). Polymorphonuclear leukocyte apoptosis is inhibited by platelet-released mediators, role of TGFbeta-1. Thromb. Haemost. 84 478–483.

    Not in our library

  24. 24.

    Bulut D. Becker V. Mugge A. (2011 ). Acetylsalicylate reduces endothelial and platelet-derived microparticles in patients with coronary artery disease. Can. J. Physiol. Pharmacol. 89 239–244.

    Not in our library10.1139/y11-013

  25. 25.

    Bulut D. Tuns H. Mugge A. (2009 ). CD31+/Annexin V+ microparticles in healthy offsprings of patients with coronary artery disease. Eur. J. Clin. Invest. 39 17–22.

    Not in our library10.1111/j.1365-2362.2008.02058.x

  26. 26.

    Butenas S. Bouchard B. A. Brummel-Ziedins K. E. Parhami-Seren B. Mann K. G. (2005 ). Tissue factor activity in whole blood. Blood 105 2764–2770.

    Not in our library10.1182/blood-2004-09-3567

  27. 27.

    Caby M. P. Lankar D. Vincendeau-Scherrer C. Raposo G. Bonnerot C. (2005 ). Exosomal-like vesicles are present in human blood plasma. Int. Immunol. 17 879–887.

    Not in our library10.1093/intimm/dxh267

  28. 28.

    Camera M. Brambilla M. Toschi V. Tremoli E. (2010 ). Tissue factor expression on platelets is a dynamic event. Blood 116 5076–5077.

    Not in our library10.1182/blood-2010-09-307306

  29. 29.

    Campello E. Spiezia L. Radu C. M. Dhima S. Visentin S. Valle F. D. (2015 ). Circulating microparticles in umbilical cord blood in normal pregnancy and pregnancy with preeclampsia. Thromb. Res. 136 427–431.

    Not in our library10.1016/j.thromres.2015.05.029

  30. 30.

    Cauwenberghs S. Feijge M. A. Harper A. G. Sage S. O. Curvers J. Heemskerk J. W. (2006 ). Shedding of procoagulant microparticles from unstimulated platelets by integrin-mediated destabilization of actin cytoskeleton. FEBS Lett. 580 5313–5320.

    Not in our library10.1016/j.febslet.2006.08.082

  31. 31.

    Chaturvedi S. Cockrell E. Espinola R. Hsi L. Fulton S. Khan M. (2015 ). Circulating microparticles in patients with antiphospholipid antibodies: characterization and associations. Thromb. Res. 135 102–108.

    Not in our library10.1016/j.thromres.2014.11.011

  32. 32.

    Chen Y. L. Chen C. H. Wallace C. G. Wang H. T. Yang C. C. Yip H. K. (2014 ). Levels of circulating microparticles in patients with chronic cardiorenal disease. J. Atheroscler. Thromb. 22 247–256.

    Not in our library10.5551/jat.26658

  33. 33.

    Chiva-Blanch G. Crespo J. Suades R. Arderiu G. Padro T. Vilahur G. (2016a ). CD142+/CD61+, CD146+ and CD45+ microparticles predict cardiovascular events in high risk patients following a Mediterranean diet supplemented with nuts. Thromb. Haemost. 116 103–114.

    Not in our library10.1160/th16-02-0130

  34. 34.

    Chiva-Blanch G. Suades R. Crespo J. Pena E. Padro T. Jimenez-Xarrie E. (2016b ). Microparticle shedding from neural progenitor cells and vascular compartment cells is increased in ischemic stroke. PLoS ONE 11:e0148176

    Not in our library10.1371/journal.pone.0148176

  35. 35.

    Chiva-Blanch G. Suades R. Crespo J. Vilahur G. Arderiu G. Padro T. (2016c ). CD3(+)/CD45(+) and SMA-alpha(+) circulating microparticles are increased in individuals at high cardiovascular risk who will develop a major cardiovascular event. Int. J. Cardiol. 208 147–149.

    Not in our library10.1016/j.ijcard.2016.01.211

  36. 36.

    Chiva-Blanch G. Suades R. Padro T. Vilahur G. Pena E. Ybarra J. (2016d ). Microparticle shedding by erythrocytes, monocytes and vascular smooth muscular cells is reduced by aspirin in diabetic patients. Rev. Esp. Cardiol. (Engl. Ed.) 69 672–680.

    Not in our library10.1016/j.rec.2015.12.033

  37. 37.

    Chou J. Mackman N. Merrill-Skoloff G. Pedersen B. Furie B. C. Furie B. (2004 ). Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation. Blood 104 3190–3197.

    Not in our library10.1182/blood-2004-03-0935

  38. 38.

    Chou Y. I. Kong J. Song R. Yan L. Zheng L. Zhang Y. (2014 ). Correlations of platelet-derived microparticles with thromboxane B2, platelet-activating factor, endothelin-1 and neutrophil to lymphocyte ratio in patients with coronary intermediate lesions. Biomarkers 19 684–692.

    Not in our library10.3109/1354750x.2014.981293

  39. 39.

    Chung A. W. Radomski A. Alonso-Escolano D. Jurasz P. Stewart M. W. Malinski T. (2004 ). Platelet-leukocyte aggregation induced by PAR agonists: regulation by nitric oxide and matrix metalloproteinases. Br. J. Pharmacol. 143 845–855.

    Not in our library10.1038/sj.bjp.0705997

  40. 40.

    Chung J. Suzuki H. Tabuchi N. Sato K. Shibamiya A. Koyama T. (2007 ). Identification of tissue factor and platelet-derived particles on leukocytes during cardiopulmonary bypass by flow cytometry and immunoelectron microscopy. Thromb. Haemost. 98 368–374.

    Not in our library

  41. 41.
    The exposure of autoantigens by microparticles underlies the formation of potent inflammatory components: the microparticle‐associated immune complexes · 2012
    No notice
  42. 42.

    Connor D. E. Exner T. Ma D. D. Joseph J. E. (2009 ). Detection of the procoagulant activity of microparticle-associated phosphatidylserine using XACT. Blood Coagul. Fibrinolysis 20 558–564.

    Not in our library10.1097/mbc.0b013e32832ee915

  43. 43.

    Connor D. E. Exner T. Ma D. D. Joseph J. E. (2010 ). The majority of circulating platelet-derived microparticles fail to bind annexin V, lack phospholipid-dependent procoagulant activity and demonstrate greater expression of glycoprotein Ib. Thromb. Haemost. 103 1044–1052.

    Not in our library10.1160/th09-09-0644

  44. 44.

    Csongrádi, É Nagy B. Jr. Fulop T. Varga Z. Karányi Z. Magyar M. T. (2011 ). Increased levels of platelet activation markers are positively associated with carotid wall thickness and other atherosclerotic risk factors in obese patients. Thromb. Haemost. 106 683–692.

    Not in our library10.1160/th11-01-0030

  45. 45.

    Cui Y. Zheng L. Jiang M. Jia R. Zhang X. Quan Q. (2013 ). Circulating microparticles in patients with coronary heart disease and its correlation with interleukin-6 and C-reactive protein. Mol. Biol. Rep. 40 6437–6442.

    Not in our library10.1007/s11033-013-2758-1

  46. 46.

    Dasgupta S. K. Abdel-Monem H. Niravath P. Le A. Bellera R. V. Langlois K. (2009 ). Lactadherin and clearance of platelet-derived microvesicles. Blood 113 1332–1339.

    Not in our library10.1182/blood-2008-07-167148

  47. 47.

    Dean W. L. Lee M. J. Cummins T. D. Schultz D. J. Powell D. W. (2009 ). Proteomic and functional characterisation of platelet microparticle size classes. Thromb. Haemost. 102 711–718.

    Not in our library10.1160/th09-04-243

  48. 48.

    Dinkla S. van Cranenbroek B. van der Heijden W. A. He X. Wallbrecher R. Dumitriu I. E. (2016 ). Platelet-derived microparticles inhibit IL-17 production by regulatory T cells through P-selectin. Blood 127 1976–1986.

    Not in our library10.1182/blood-2015-04-640300

  49. 49.

    Eckstein F. M. Xiang W. Weiss D. R. Zimmermann R. Strasser E. F. (2014 ). The influence of pre-analytical conditions on platelet-derived microparticles. Clin. Lab. 60 707–716.

    Not in our library10.7754/clin.lab.2013.130604

  50. 50.

    Escolar G. Lopez-Vilchez I. Diaz-Ricart M. White J. G. Galan A. M. (2008 ). Internalization of tissue factor by platelets. Thromb. Res. 122(Suppl. 1), S37–S41.

    Not in our library10.1016/s0049-3848(08)70017-3

  51. 51.

    Flaumenhaft R. (2006 ). Formation and fate of platelet microparticles. Blood Cells Mol. Dis. 36 182–187.

    Not in our library10.1016/j.bcmd.2005.12.019

  52. 52.

    Flaumenhaft R. Dilks J. R. Richardson J. Alden E. Patel-Hett S. R. Battinelli E. (2009 ). Megakaryocyte-derived microparticles: direct visualization and distinction from platelet-derived microparticles. Blood 113 1112–1121.

    Not in our library10.1182/blood-2008-06-163832

  53. 53.

    Forlow S. B. McEver R. P. Nollert M. U. (2000 ). Leukocyte-leukocyte interactions mediated by platelet microparticles under flow. Blood 95 1317–1323.

    Not in our library

  54. 54.

    Franca C. N. Pinheiro L. F. Izar M. C. Brunialti M. K. Salomao R. Bianco H. T. (2012 ). Endothelial progenitor cell mobilization and platelet microparticle release are influenced by clopidogrel plasma levels in stable coronary artery disease. Circ. J. 76 729–736.

    Not in our library10.1253/circj.cj-11-1145

  55. 55.

    Fuentes Q. E. Fuentes Q. F. Andres V. Pello O. M. de Mora J. F. Palomo G. I. (2013 ). Role of platelets as mediators that link inflammation and thrombosis in atherosclerosis. Platelets 24 255–262.

    Not in our library10.3109/09537104.2012.690113

  56. 56.

    Fuster V. Stein B. Ambrose J. A. Badimon L. Badimon J. J. Chesebro J. H. (1990 ). Atherosclerotic plaque rupture and thrombosis. Evolving concepts. Circulation 82(3Suppl.), II47–II59.

    Not in our library

  57. 57.
    Platelet-derived exosomes induce endothelial cell apoptosis through peroxynitrite generation: experimental evidence for a novel mechanism of septic vascular dysfunction · 2007
    No notice
  58. 58.

    Garcia B. A. Smalley D. M. Cho H. Shabanowitz J. Ley K. Hunt D. F. (2005 ). The platelet microparticle proteome. J. Proteome Res. 4 1516–1521.

    Not in our library10.1021/pr0500760

  59. 59.

    Gatsiou A. Boeckel J. N. Randriamboavonjy V. Stellos K. (2012 ). MicroRNAs in platelet biogenesis and function: implications in vascular homeostasis and inflammation. Curr. Vasc. Pharmacol. 10 524–531.

    Not in our library10.2174/157016112801784611

  60. 60.

    Gemmell C. H. Sefton M. V. Yeo E. L. (1993 ). Platelet-derived microparticle formation involves glycoprotein IIb-IIIa. Inhibition by RGDS and a Glanzmann’s thrombasthenia defect. J. Biol. Chem. 268 14586–14589.

    Not in our library

  61. 61.

    Gemmell C. H. Yeo E. L. Sefton M. V. (1997 ). Flow cytometric analysis of material-induced platelet activation in a canine model: elevated microparticle levels and reduced platelet life span. J. Biomed. Mater. Res. 37 176–181.

    Not in our library10.1002/(sici)1097-4636(199711)37:2<176::aid-jbm5>3.0.co;2-o

  62. 62.

    George M. Ganesh M. R. Sridhar A. Jena A. Rajaram M. Shanmugam E. (2015 ). Evaluation of endothelial and platelet derived microparticles in patients with acute coronary syndrome. J. Clin. Diagn. Res. 9 OC09–OC13.

    Not in our library10.7860/jcdr/2015/14493.6920

  63. 63.

    Getts D. R. Terry R. L. Getts M. T. Deffrasnes C. Muller M. van Vreden C. (2014 ). Therapeutic inflammatory monocyte modulation using immune-modifying microparticles. Sci. Transl. Med. 6 219ra217.

    Not in our library10.1126/scitranslmed.3007563

  64. 64.

    Gidlof O. van der Brug M. Ohman J. Gilje P. Olde B. Wahlestedt C. (2013 ). Platelets activated during myocardial infarction release functional miRNA, which can be taken up by endothelial cells and regulate ICAM1 expression. Blood 121 3908–3917.

    Not in our library10.1182/blood-2012-10-461798

  65. 65.

    Gilbert G. E. Sims P. J. Wiedmer T. Furie B. Furie B. C. Shattil S. J. (1991 ). Platelet-derived microparticles express high affinity receptors for factor VIII. J. Biol. Chem. 266 17261–17268.

    Not in our library

  66. 66.

    Gitz E. Pollitt A. Y. Gitz-Francois J. J. Alshehri O. Mori J. Montague S. (2014 ). CLEC-2 expression is maintained on activated platelets and on platelet microparticles. Blood 124 2262–2270.

    Not in our library10.1182/blood-2014-05-572818

  67. 67.

    Goto S. Tamura N. Li M. Handa M. Ikeda Y. Handa S. (2003 ). Different effects of various anti-GPIIb-IIIa agents on shear-induced platelet activation and expression of procoagulant activity. J. Thromb. Haemost. 1 2022–2030.

    Not in our library10.1046/j.1538-7836.2003.00349.x

  68. 68.

    Goudevenos J. Tselepis A. D. Vini M. P. Michalis L. Tsoukatos D. C. Elisaf M. (2001 ). Platelet-associated and secreted PAF-acetylhydrolase activity in patients with stable angina: sequential changes of the enzyme activity after angioplasty. Eur. J. Clin. Invest. 31 15–23.

    Not in our library10.1046/j.1365-2362.2001.00782.x

  69. 69.

    Grant R. Ansa-Addo E. Stratton D. Antwi-Baffour S. Jorfi S. Kholia S. (2011 ). A filtration-based protocol to isolate human plasma membrane-derived vesicles and exosomes from blood plasma. J. Immunol. Methods 371 143–151.

    Not in our library10.1016/j.jim.2011.06.024

  70. 70.

    Gustafson C. M. Shepherd A. J. Miller V. M. Jayachandran M. (2015 ). Age- and sex-specific differences in blood-borne microvesicles from apparently healthy humans. Biol. Sex Differ. 6 10

    Not in our library10.1186/s13293-015-0028-8

  71. 71.

    Hayon Y. Dashevsky O. Shai E. Brill A. Varon D. Leker R. R. (2012 ). Platelet microparticles induce angiogenesis and neurogenesis after cerebral ischemia. Curr. Neurovasc. Res. 9 185–192.

    Not in our library10.2174/156720212801619018

  72. 72.

    Heijnen H. F. Schiel A. E. Fijnheer R. Geuze H. J. Sixma J. J. (1999 ). Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules. Blood 94 3791–3799.

    Not in our library

  73. 73.

    Helal O. Defoort C. Robert S. Marin C. Lesavre N. Lopez-Miranda J. (2011 ). Increased levels of microparticles originating from endothelial cells, platelets and erythrocytes in subjects with metabolic syndrome: relationship with oxidative stress. Nutr. Metab. Cardiovasc. Dis. 21 665–671.

    Not in our library10.1016/j.numecd.2010.01.004

  74. 74.

    Herring J. M. McMichael M. A. Smith S. A. (2013 ). Microparticles in health and disease. J. Vet. Intern. Med. 27 1020–1033.

    Not in our library10.1111/jvim.12128

  75. 75.

    Holme P. A. Brosstad F. Solum N. O. (1993 ). The difference between platelet and plasma FXIII used to study the mechanism of platelet microvesicle formation. Thromb. Haemost. 70 681–686.

    Not in our library

  76. 76.

    Horigome H. Hiramatsu Y. Shigeta O. Nagasawa T. Matsui A. (2002 ). Overproduction of platelet microparticles in cyanotic congenital heart disease with polycythemia. J. Am. Coll. Cardiol. 39 1072–1077.

    Not in our library10.1016/s0735-1097(02)01718-7

  77. 77.

    Horn P. Baars T. Kahlert P. Heiss C. Westenfeld R. Kelm M. (2015 ). Release of intracoronary microparticles during stent implantation into stable atherosclerotic lesions under protection with an aspiration device. PLoS ONE 10:e0124904

    Not in our library10.1371/journal.pone.0124904

  78. 78.

    Horstman L. L. Ahn Y. S. (1999 ). Platelet microparticles: a wide-angle perspective. Crit. Rev. Oncol. Hematol. 30 111–142.

    Not in our library10.1016/s1040-8428(98)00044-4

  79. 79.

    Hristov M. Erl W. Linder S. Weber P. C. (2004 ). Apoptotic bodies from endothelial cells enhance the number and initiate the differentiation of human endothelial progenitor cells in vitro. Blood 104 2761–2766.

    Not in our library10.1182/blood-2003-10-3614

  80. 80.

    Hugel B. Socie G. Vu T. Toti F. Gluckman E. Freyssinet J. M. (1999 ). Elevated levels of circulating procoagulant microparticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anemia. Blood 93 3451–3456.

    Not in our library

  81. 81.

    Hulsmans M. Holvoet P. (2013 ). MicroRNA-containing microvesicles regulating inflammation in association with atherosclerotic disease. Cardiovasc. Res. 100 7–18.

    Not in our library10.1093/cvr/cvt161

  82. 82.

    Inoue T. Hikichi Y. Morooka T. Yoshida K. Fujimatsu D. Komoda H. (2006 ). Comparison of changes in circulating platelet-derived microparticles and platelet surface P-selectin expression after coronary stent implantation. Platelets 17 416–420.

    Not in our library10.1080/09537100600757885

  83. 83.

    Inoue T. Komoda H. Kotooka N. Morooka T. Fujimatsu D. Hikichi Y. (2008 ). Increased circulating platelet-derived microparticles are associated with stent-induced vascular inflammation. Atherosclerosis 196 469–476.

    Not in our library10.1016/j.atherosclerosis.2006.12.004

  84. 84.

    Ismail E. A. Youssef O. I. (2012 ). Platelet-derived microparticles and platelet function profile in children with congenital heart disease. Clin. Appl. Thromb. Hemost. 19 424–432.

    Not in our library10.1177/1076029612456733

  85. 85.

    Italiano J. E. Jr. Richardson J. L. Patel-Hett S. Battinelli E. Zaslavsky A. Short S. (2008 ). Angiogenesis is regulated by a novel mechanism: pro-and antiangiogenic proteins are organized into separate plateletalpha granules and differentially released. Blood 111 1227–1233.

    Not in our library10.1182/blood-2007-09-113837

  86. 86.

    Iwamoto S. Kawasaki T. Kambayashi J. Ariyoshi H. Monden M. (1996 ). Platelet microparticles: a carrier of platelet-activating factor? Biochem. Biophys. Res. Commun. 218 940–944.

    Not in our library10.1006/bbrc.1996.0166

  87. 87.

    Janiszewski M. Do Carmo A. O. Pedro M. A. Silva E. Knobel E. Laurindo F. R. (2004 ). Platelet-derived exosomes of septic individuals possess proapoptotic NAD(P)H oxidase activity: a novel vascular redox pathway. Crit. Care Med. 32 818–825.

    Not in our library10.1097/01.ccm.0000114829.17746.19

  88. 88.

    Jayachandran M. Litwiller R. D. Owen W. G. Heit J. A. Behrenbeck T. Mulvagh S. L. (2008 ). Characterization of blood borne microparticles as markers of premature coronary calcification in newly menopausal women. Am. J. Physiol. Heart Circ. Physiol. 295 H931–H938.

    Not in our library10.1152/ajpheart.00193.2008

  89. 89.

    Jimenez J. J. Jy W. Mauro L. M. Soderland C. Horstman L. L. Ahn Y. S. (2003 ). Endothelial cells release phenotypically and quantitatively distinct microparticles in activation and apoptosis. Thromb. Res. 109 175–180.

    Not in our library10.1016/s0049-3848(03)00064-1

  90. 90.

    Juan-Babot J. O. Martinez-Gonzalez J. Berrozpe M. Badimon L. (2003 ). [Neovascularization in human coronary arteries with lesions of different severity]. Rev. Esp. Cardiol. 56 978–986.

    Not in our library10.1016/s0300-8932(03)76995-4

  91. 91.

    Judge H. M. Buckland R. J. Sugidachi A. Jakubowski J. A. Storey R. F. (2010 ). Relationship between degree of P2Y12 receptor blockade and inhibition of P2Y12-mediated platelet function. Thromb. Haemost. 103 1210–1217.

    Not in our library10.1160/th09-11-0770

  92. 92.

    Jung C. Sorensson P. Saleh N. Arheden H. Ryden L. Pernow J. (2012 ). Circulating endothelial and platelet derived microparticles reflect the size of myocardium at risk in patients with ST-elevation myocardial infarction. Atherosclerosis 221 226–231.

    Not in our library10.1016/j.atherosclerosis.2011.12.025

  93. 93.

    Jy W. Mao W. W. Horstman L. Tao J. Ahn Y. S. (1995 ). Platelet microparticles bind, activate and aggregate neutrophils in vitro. Blood Cells Mol. Dis. 21 217–231.

    Not in our library10.1006/bcmd.1995.0025

  94. 94.

    Kagawa H. Nomura S. Nagahama M. Ozaki Y. Fukuhara S. (2001 ). Effect of bezafibrate on soluble adhesion molecules and platelet activation markers in patients with connective tissue diseases and secondary hyperlipidemia. Clin. Appl. Thromb. Hemost. 7 153–157.

    Not in our library10.1177/107602960100700213

  95. 95.

    Kahner B. N. Dorsam R. T. Kunapuli S. P. (2008 ). Role of P2Y receptor subtypes in platelet-derived microparticle generation. Front. Biosci. 13:433–439.

    Not in our library10.2741/2690

  96. 96.

    Kaneider N. C. Kaser A. Tilg H. Ricevuti G. Wiedermann C. J. (2003 ). CD40 ligand-dependent maturation of human monocyte-derived dendritic cells by activated platelets. Int. J. Immunopathol. Pharmacol. 16 225–231.

    Not in our library10.1177/039463200301600307

  97. 97.

    Kawamoto A. Tkebuchava T. Yamaguchi J. Nishimura H. Yoon Y. S. Milliken C. (2003 ). Intramyocardial transplantation of autologous endothelial progenitor cells for therapeutic neovascularization of myocardial ischemia. Circulation 107 461–468.

    Not in our library10.1161/01.cir.0000046450.89986.50

  98. 98.

    Kim H. K. Song K. S. Chung J. H. Lee K. R. Lee S. N. (2004 ). Platelet microparticles induce angiogenesis in vitro. Br. J. Haematol. 124 376–384.

    Not in our library10.1046/j.1365-2141.2003.04773.x

  99. 99.

    Kuriyama N. Nagakane Y. Hosomi A. Ohara T. Kasai T. Harada S. (2010 ). Evaluation of factors associated with elevated levels of platelet-derived microparticles in the acute phase of cerebral infarction. Clin. Appl. Thromb. Hemost. 16 26–32.

    Not in our library10.1177/1076029609338047

  100. 100.

    Laffont B. Corduan A. Ple H. Duchez A. C. Cloutier N. Boilard E. (2013 ). Activated platelets can deliver mRNA regulatory Ago2∗microRNA complexes to endothelial cells via microparticles. Blood 122 253–261.

    Not in our library10.1182/blood-2013-03-492801

  101. 101.

    Leroyer A. S. Isobe H. Leseche G. Castier Y. Wassef M. Mallat Z. (2007 ). Cellular origins and thrombogenic activity of microparticles isolated from human atherosclerotic plaques. J. Am. Coll. Cardiol. 49 772–777.

    Not in our library10.1016/j.jacc.2006.10.053

  102. 102.

    Lin H. C. Chang H. W. Hsiao S. H. Chou M. L. Seghatchian J. Burnouf T. (2015 ). Platelet-derived microparticles trigger THP-1 monocytic cell aggregation and release of pro-coagulant tissue factor-expressing microparticles in vitro. Transfus. Apher. Sci. 53 246–252.

    Not in our library10.1016/j.transci.2015.10.002

  103. 103.

    Lindemann S. Tolley N. D. Dixon D. A. McIntyre T. M. Prescott S. M. Zimmerman G. A. (2001 ). Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis. J. Cell Biol. 154 485–490.

    Not in our library10.1083/jcb.200105058

  104. 104.

    Lopez-Vilchez I. Escolar G. Diaz-Ricart M. Fuste B. Galan A. M. White J. G. (2007 ). Tissue factor-enriched vesicles are taken up by platelets and induce platelet aggregation in the presence of factor VIIa. Thromb. Haemost. 97 202–211.

    Not in our library

  105. 105.

    Lopez-Vilchez I. Galan A. M. Hernandez M. R. Caballo C. Roque M. Diaz-Ricart M. (2012 ). Platelet-associated tissue factor enhances platelet reactivity and thrombin generation in experimental studies in vitro. Thromb. Res. 130 e294–e300.

    Not in our library10.1016/j.thromres.2012.10.003

  106. 106.

    Lösche W. Scholz T. Temmler U. Oberle V. Claus R. A. (2004 ). Platelet-derived microvesicles transfer tissue factor to monocytes but not to neutrophils. Platelets 15 109–115.

    Not in our library10.1080/09537100310001649885

  107. 107.

    Losito I. Conte E. Cataldi T. R. Cioffi N. Megli F. M. Palmisano F. (2015 ). The phospholipidomic signatures of human blood microparticles, platelets and platelet-derived microparticles: a comparative HILIC-ESI-MS investigation. Lipids 50 71–84.

    Not in our library10.1007/s11745-014-3975-7

  108. 108.

    Lubsczyk B. Kollars M. Hron G. Kyrle P. A. Weltermann A. Gartner V. (2010 ). Low dose acetylsalicylic acid and shedding of microparticles in vivo in humans. Eur. J. Clin. Invest. 40 477–482.

    Not in our library10.1111/j.1365-2362.2010.02299.x

  109. 109.

    Lukasik M. Rozalski M. Luzak B. Michalak M. Ambrosius W. Watala C. (2013 ). Enhanced platelet-derived microparticle formation is associated with carotid atherosclerosis in convalescent stroke patients. Platelets 24 63–70.

    Not in our library10.3109/09537104.2011.654292

  110. 110.

    Ma F. Liu H. Shen Y. Zhang Y. Pan S. (2015 ). Platelet-derived microvesicles are involved in cardio-protective effects of remote preconditioning. Int. J. Clin. Exp. Pathol. 8 10832–10839.

    Not in our library

  111. 111.

    Marenberg M. E. Risch N. Berkman L. F. Floderus B. de Faire U. (1994 ). Genetic susceptibility to death from coronary heart disease in a study of twins. N. Engl. J. Med. 330 1041–1046.

    Not in our library10.1056/nejm199404143301503

  112. 112.

    Mause S. F. (2013 ). Platelet microparticles: reinforcing the hegemony of platelets in atherothrombosis. Thromb. Haemost. 109 5–6.

    Not in our library10.1160/th12-11-0817

  113. 113.

    Mause S. F. Ritzel E. Liehn E. A. Hristov M. Bidzhekov K. Muller-Newen G. (2010 ). Platelet microparticles enhance the vasoregenerative potential of angiogenic early outgrowth cells after vascular injury. Circulation 122 495–506.

    Not in our library10.1161/circulationaha.109.909473

  114. 114.

    Mause S. F. von Hundelshausen P. Zernecke A. Koenen R. R. Weber C. (2005 ). Platelet microparticles: a transcellular delivery system for RANTES promoting monocyte recruitment on endothelium. Arterioscler. Thromb. Vasc. Biol. 25 1512–1518.

    Not in our library10.1161/01.atv.0000170133.43608.37

  115. 115.

    McCarthy M. J. Loftus I. M. Thompson M. M. Jones L. London N. J. Bell P. R. (1999 ). Angiogenesis and the atherosclerotic carotid plaque: an association between symptomatology and plaque morphology. J. Vasc. Surg. 30 261–268.

    Not in our library10.1016/s0741-5214(99)70136-9

  116. 116.

    Merten M. Pakala R. Thiagarajan P. Benedict C. R. (1999 ). Platelet microparticles promote platelet interaction with subendothelial matrix in a glycoprotein IIb/IIIa-dependent mechanism. Circulation 99 2577–2582.

    Not in our library10.1161/01.cir.99.19.2577

  117. 117.

    Meziani F. Tesse A. Andriantsitohaina R. (2008 ). Microparticles are vectors of paradoxical information in vascular cells including the endothelium: role in health and diseases. Pharmacol. Rep. 60 75–84.

    Not in our library

  118. 118.

    Michelsen A. E. Brodin E. Brosstad F. Hansen J. B. (2008 ). Increased level of platelet microparticles in survivors of myocardial infarction. Scand. J. Clin. Lab. Invest. 68 386–392.

    Not in our library10.1080/00365510701794957

  119. 119.

    Milioli M. Ibanez-Vea M. Sidoli S. Palmisano G. Careri M. Larsen M. R. (2015 ). Quantitative proteomics analysis of platelet-derived microparticles reveals distinct protein signatures when stimulated by different physiological agonists. J. Proteomics 121 56–66.

    Not in our library10.1016/j.jprot.2015.03.013

  120. 120.

    Mitsios J. V. Vini M. P. Stengel D. Ninio E. Tselepis A. D. (2006 ). Human platelets secrete the plasma type of platelet-activating factor acetylhydrolase primarily associated with microparticles. Arterioscler. Thromb. Vasc. Biol. 26 1907–1913.

    Not in our library10.1161/01.atv.0000228821.79588.ef

  121. 121.

    Miyazaki Y. Nomura S. Miyake T. Kagawa H. Kitada C. Taniguchi H. (1996 ). High shear stress can initiate both platelet aggregation and shedding of procoagulant containing microparticles. Blood 88 3456–3464.

    Not in our library

  122. 122.

    Miyazono K. Okabe T. Urabe A. Yamanaka M. Takaku F. (1985 ). A platelet factor that stimulates the proliferation of vascular endothelial cells. Biochem. Biophys. Res. Commun. 126 83–88.

    Not in our library10.1016/0006-291x(85)90574-1

  123. 123.

    Mobarrez F. He S. Broijersen A. Wiklund B. Antovic A. Antovic J. (2011 ). Atorvastatin reduces thrombin generation and expression of tissue factor, P-selectin and GPIIIa on platelet-derived microparticles in patients with peripheral arterial occlusive disease. Thromb. Haemost. 106 344–352.

    Not in our library10.1160/th10-12-0810

  124. 124.

    Monkovic D. D. Tracy P. B. (1990 ). Functional characterization of human platelet-released factor V and its activation by factor Xa and thrombin. J. Biol. Chem. 265 17132–17140.

    Not in our library

  125. 125.

    Montoro-Garcia S. Shantsila E. Hernandez-Romero D. Jover E. Valdes M. Marin F. (2014 ). Small-size platelet microparticles trigger platelet and monocyte functionality and modulate thrombogenesis via P-selectin. Br. J. Haematol. 166 571–580.

    Not in our library10.1111/bjh.12913

  126. 126.

    Morel O. Hugel B. Jesel L. Mallat Z. Lanza F. Douchet M. P. (2004 ). Circulating procoagulant microparticles and soluble GPV in myocardial infarction treated by primary percutaneous transluminal coronary angioplasty. A possible role for GPIIb-IIIa antagonists. J. Thromb. Haemost. 2 1118–1126.

    Not in our library10.1111/j.1538-7836.2004.00805.x

  127. 127.

    Morel O. Jesel L. Hugel B. Douchet M. P. Zupan M. Chauvin M. (2003 ). Protective effects of vitamin C on endothelium damage and platelet activation during myocardial infarction in patients with sustained generation of circulating microparticles. J. Thromb. Haemost. 1 171–177.

    Not in our library10.1046/j.1538-7836.2003.00010.x

  128. 128.

    Mujica V. Urzua A. Leiva E. Diaz N. Moore-Carrasco R. Vasquez M. (2010 ). Intervention with education and exercise reverses the metabolic syndrome in adults. J. Am. Soc. Hypertens. 4 148–153.

    Not in our library10.1016/j.jash.2010.02.008

  129. 129.

    Murakami T. Horigome H. Tanaka K. Nakata Y. Ohkawara K. Katayama Y. (2007 ). Impact of weight reduction on production of platelet-derived microparticles and fibrinolytic parameters in obesity. Thromb. Res. 119 45–53.

    Not in our library10.1016/j.thromres.2005.12.013

  130. 130.

    Namba M. Tanaka A. Shimada K. Ozeki Y. Uehata S. Sakamoto T. (2007 ). Circulating platelet-derived microparticles are associated with atherothrombotic events: a marker for vulnerable blood. Arterioscler. Thromb. Vasc. Biol. 27 255–256.

    Not in our library10.1161/01.atv.0000252064.97632.2c

  131. 131.

    Nebor D. Bowers A. Connes P. Hardy-Dessources M. D. Knight-Madden J. Cumming V. (2014 ). Plasma concentration of platelet-derived microparticles is related to painful vaso-occlusive phenotype severity in sickle cell anemia. PLoS ONE 9:e87243

    Not in our library10.1371/journal.pone.0087243

  132. 132.

    Nishijima K. Kiryu J. Tsujikawa A. Miyamoto K. Honjo M. Tanihara H. (2004 ). Platelets adhering to the vascular wall mediate postischemic leukocyte-endothelial cell interactions in retinal microcirculation. Invest. Ophthalmol. Vis. Sci. 45 977–984.

    Not in our library10.1167/iovs.03-0526

  133. 133.

    Nomura S. Nakamura T. Cone J. Tandon N. N. Kambayashi J. (2000 ). Cytometric analysis of high shear-induced platelet microparticles and effect of cytokines on microparticle generation. Cytometry 40 173–181.

    Not in our library10.1002/1097-0320(20000701)40:3<173::aid-cyto1>3.0.co;2-l

  134. 134.

    Nomura S. Omoto S. Yokoi T. Fujita S. Ozasa R. Eguchi N. (2011 ). Effects of miglitol in platelet-derived microparticle, adiponectin, and selectin level in patients with type 2 diabetes mellitus. Int. J. Gen. Med. 4 539–545.

    Not in our library10.2147/ijgm.s22115

  135. 135.

    Nomura S. Shouzu A. Omoto S. Nishikawa M. Fukuhara S. Iwasaka T. (2004a ). Losartan and simvastatin inhibit platelet activation in hypertensive patients. J. Thromb. Thrombolysis 18 177–185.

    Not in our library10.1007/s11239-005-0343-8

  136. 136.

    Nomura S. Shouzu A. Omoto S. Nishikawa M. Iwasaka T. Fukuhara S. (2004b ). Activated platelet and oxidized LDL induce endothelial membrane vesiculation: clinical significance of endothelial cell-derived microparticles in patients with type 2 diabetes. Clin. Appl. Thromb. Hemost. 10 205–215.

    Not in our library10.1177/107602960401000302

  137. 137.

    Nomura S. Takahashi N. Inami N. Kajiura T. Yamada K. Nakamori H. (2004c ). Probucol and ticlopidine: effect on platelet and monocyte activation markers in hyperlipidemic patients with and without type 2 diabetes. Atherosclerosis 174 329–335.

    Not in our library10.1016/j.atherosclerosis.2004.01.027

  138. 138.

    Nomura S. Shouzu A. Omoto S. Nishikawa M. Iwasaka T. (2005a ). Benidipine improves oxidized LDL-dependent monocyte and endothelial dysfunction in hypertensive patients with type 2 diabetes mellitus. J. Hum. Hypertens. 19 551–557.

    Not in our library10.1038/sj.jhh.1001863

  139. 139.

    Nomura S. Shouzu A. Omoto S. Nishikawa M. Iwasaka T. (2005b ). Long-term treatment with nifedipine modulates procoagulant marker and C-C chemokine in hypertensive patients with type 2 diabetes mellitus. Thromb. Res. 115 277–285.

    Not in our library10.1016/j.thromres.2004.08.015

  140. 140.

    Nomura S. Suzuki M. Katsura K. Xie G. L. Miyazaki Y. Miyake T. (1995 ). Platelet-derived microparticles may influence the development of atherosclerosis in diabetes mellitus. Atherosclerosis 116 235–240.

    Not in our library10.1016/0021-9150(95)05551-7

  141. 141.

    Nomura S. Tandon N. N. Nakamura T. Cone J. Fukuhara S. Kambayashi J. (2001 ). High-shear-stress-induced activation of platelets and microparticles enhances expression of cell adhesion molecules in THP-1 and endothelial cells. Atherosclerosis 158 277–287.

    Not in our library10.1016/s0021-9150(01)00433-6

  142. 142.

    Oberle V. Fischer A. Setzer F. Losche W. (2007 ). Thrombus formation without platelets under inflammatory condition: an in vitro study. Platelets 18 143–149.

    Not in our library10.1080/09537100600935176

  143. 143.

    Ohtsuka M. Sasaki K. Ueno T. Seki R. Nakayoshi T. Koiwaya H. (2013 ). Platelet-derived microparticles augment the adhesion and neovascularization capacities of circulating angiogenic cells obtained from atherosclerotic patients. Atherosclerosis 227 275–282.

    Not in our library10.1016/j.atherosclerosis.2013.01.040

  144. 144.

    Ohuchi M. Fujino K. Kishimoto T. Yamane T. Hamamoto T. Tabata T. (2015 ). Association of the plasma platelet-derived microparticles to platelet count ratio with hospital mortality and disseminated intravascular coagulopathy in critically lll patients. J. Atheroscler. Thromb. 22 773–782.

    Not in our library10.5551/jat.29439

  145. 145.

    Ottaviani L. De Windt L. J. da Costa Martins P. A. (2016 ). Exosomes: scytales in the damaged heart. Ann. Transl. Med. 4 222

    Not in our library10.21037/atm.2016.05.17

  146. 146.

    Owens M. R. (1994 ). The role of platelet microparticles in hemostasis. Transfus. Med. Rev. 8 37–44.

    Not in our library10.1016/s0887-7963(94)70096-1

  147. 147.

    Pakala R. (2004 ). Serotonin and thromboxane A2 stimulate platelet-derived microparticle-induced smooth muscle cell proliferation. Cardiovasc. Radiat. Med. 5 20–26.

    Not in our library10.1016/j.carrad.2003.12.002

  148. 148.

    Palomo I. Toro C. Alarcon M. (2008 ). The role of platelets in the pathophysiology of atherosclerosis (Review). Mol. Med. Rep. 1 179–184.

    Not in our library

  149. 149.

    Palomo I. F. Torres G. I. Alarcon M. A. Maragano P. J. Leiva E. Mujica V. (2006 ). [High prevalence of classic cardiovascular risk factors in a population of university students from south central Chile]. Rev. Esp. Cardiol. 59 1099–1105.

    Not in our library10.1157/13095778

  150. 150.

    Pasquet J. M. Dachary-Prigent J. Nurden A. T. (1996 ). Calcium influx is a determining factor of calpain activation and microparticle formation in platelets. Eur. J. Biochem. 239 647–654.

    Not in our library10.1111/j.1432-1033.1996.0647u.x

  151. 151.

    Pawelczyk M. Chmielewski H. Kaczorowska B. Przybyla M. Baj Z. (2015 ). The influence of statin therapy on platelet activity markers in hyperlipidemic patients after ischemic stroke. Arch. Med. Sci. 11 115–121.

    Not in our library10.5114/aoms.2015.49216

  152. 152.

    Perez-Pujol S. Marker P. H. Key N. S. (2007 ). Platelet microparticles are heterogeneous and highly dependent on the activation mechanism: studies using a new digital flow cytometer. Cytometry A 71 38–45.

    Not in our library10.1002/cyto.a.20354

  153. 153.

    Prasad K. S. Andre P. He M. Bao M. Manganello J. Phillips D. R. (2003 ). Soluble CD40 ligand induces beta3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling. Proc. Natl. Acad. Sci. U.S.A. 100 12367–12371.

    Not in our library10.1073/pnas.2032886100

  154. 154.

    Preston R. A. Jy W. Jimenez J. J. Mauro L. M. Horstman L. L. Valle M. (2003 ). Effects of severe hypertension on endothelial and platelet microparticles. Hypertension 41 211–217.

    Not in our library10.1161/01.hyp.0000049760.15764.2d

  155. 155.

    Prokopi M. Pula G. Mayr U. Devue C. Gallagher J. Xiao Q. (2009 ). Proteomic analysis reveals presence of platelet microparticles in endothelial progenitor cell cultures. Blood 114 723–732.

    Not in our library10.1182/blood-2009-02-205930

  156. 156.

    Ramacciotti E. Hawley A. E. Farris D. M. Ballard N. E. Wrobleski S. K. Myers D. D. (2009 ). Leukocyte- and platelet-derived microparticles correlate with thrombus weight and tissue factor activity in an experimental mouse model of venous thrombosis. Thromb. Haemost. 101 748–754.

    Not in our library10.1160/th08-09-0620

  157. 157.

    Rand M. L. Wang H. Bang K. W. Packham M. A. Freedman J. (2006 ). Rapid clearance of procoagulant platelet-derived microparticles from the circulation of rabbits. J. Thromb. Haemost. 4 1621–1623.

    Not in our library10.1111/j.1538-7836.2006.02011.x

  158. 158.

    Rank A. Nieuwland R. Delker R. Kohler A. Toth B. Pihusch V. (2010 ). Cellular origin of platelet-derived microparticles in vivo. Thromb Res 126 e255–e259.

    Not in our library10.1016/j.thromres.2010.07.012

  159. 159.

    Raturi A. Miersch S. Hudson J. W. Mutus B. (2008 ). Platelet microparticle-associated protein disulfide isomerase promotes platelet aggregation and inactivates insulin. Biochim. Biophys. Acta 1778 2790–2796.

    Not in our library10.1016/j.bbamem.2008.07.003

  160. 160.

    Ray D. M. Spinelli S. L. Pollock S. J. Murant T. I. O’Brien J. J. Blumberg N. (2008 ). Peroxisome proliferator-activated receptor gamma and retinoid X receptor transcription factors are released from activated human platelets and shed in microparticles. Thromb. Haemost. 99 86–95.

    Not in our library10.1160/th07-05-0328

  161. 161.

    Reininger A. J. Heijnen H. F. Schumann H. Specht H. M. Schramm W. Ruggeri Z. M. (2006 ). Mechanism of platelet adhesion to von Willebrand factor and microparticle formation under high shear stress. Blood 107 3537–3545.

    Not in our library10.1182/blood-2005-02-0618

  162. 162.

    Ren J. G. Man Q. W. Zhang W. Li C. Xiong X. P. Zhu J. Y. (2015 ). Elevated level of circulating platelet-derived microparticles in Oral Cancer. J. Dent. Res. 95 87–93.

    Not in our library10.1177/0022034515592593

  163. 163.

    Rozmyslowicz T. Majka M. Kijowski J. Murphy S. L. Conover D. O. Poncz M. (2003 ). Platelet- and megakaryocyte-derived microparticles transfer CXCR4 receptor to CXCR4-null cells and make them susceptible to infection by X4-HIV. Aids 17 33–42.

    Not in our library10.1097/00002030-200301030-00006

  164. 164.

    Sabatier F. Darmon P. Hugel B. Combes V. Sanmarco M. Velut J. G. (2002 ). Type 1 and type 2 diabetic patients display different patterns of cellular microparticles. Diabetes 51 2840–2845.

    Not in our library10.2337/diabetes.51.9.2840

  165. 165.

    Sadallah S. Amicarella F. Eken C. Iezzi G. Schifferli J. A. (2014 ). Ectosomes released by platelets induce differentiation of CD4+T cells into T regulatory cells. Thromb. Haemost. 112 1219–1229.

    Not in our library10.1160/th14-03-0281

  166. 166.

    Sadallah S. Eken C. Martin P. J. Schifferli J. A. (2011 ). Microparticles (ectosomes) shed by stored human platelets downregulate macrophages and modify the development of dendritic cells. J. Immunol. 186 6543–6552.

    Not in our library10.4049/jimmunol.1002788

  167. 167.

    Sakariassen K. S. Holme P. A. Orvim U. Barstad R. M. Solum N. O. Brosstad F. R. (1998 ). Shear-induced platelet activation and platelet microparticle formation in native human blood. Thromb. Res. 92(6 Suppl. 2), S33–S41.

    Not in our library10.1016/s0049-3848(98)00158-3

  168. 168.

    Sambola A. Osende J. Hathcock J. Degen M. Nemerson Y. Fuster V. (2003 ). Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation 107 973–977.

    Not in our library10.1161/01.cir.0000050621.67499.7d

  169. 169.

    Santos-Gallego C. G. Picatoste B. Badimon J. J. (2014 ). Pathophysiology of acute coronary syndrome. Curr. Atheroscler. Rep. 16 401

    Not in our library10.1007/s11883-014-0401-9

  170. 170.

    Sarlon-Bartoli G. Bennis Y. Lacroix R. Piercecchi-Marti M. D. Bartoli M. A. Arnaud L. (2013 ). Plasmatic level of leukocyte-derived microparticles is associated with unstable plaque in asymptomatic patients with high-grade carotid stenosis. J. Am. Coll. Cardiol. 62 1436–1441.

    Not in our library10.1016/j.jacc.2013.03.078

  171. 171.

    Setzer F. Oberle V. Blass M. Moller E. Russwurm S. Deigner H. P. (2006 ). Platelet-derived microvesicles induce differential gene expression in monocytic cells: a DNA microarray study. Platelets 17 571–576.

    Not in our library10.1080/09537100600760244

  172. 172.

    Shai E. Rosa I. Parguina A. F. Motahedeh S. Varon D. Garcia A. (2012 ). Comparative analysis of platelet-derived microparticles reveals differences in their amount and proteome depending on the platelet stimulus. J. Proteomics 76 Spec. No, 287–296.

    Not in our library10.1016/j.jprot.2012.02.030

  173. 173.

    Shan L. Y. Li J. Z. Zu L. Y. Niu C. G. Ferro A. Zhang Y. D. (2013 ). Platelet-derived microparticles are implicated in remote ischemia conditioning in a rat model of cerebral infarction. CNS Neurosci. Ther. 19 917–925.

    Not in our library10.1111/cns.12199

  174. 174.

    Siljander P. Carpen O. Lassila R. (1996 ). Platelet-derived microparticles associate with fibrin during thrombosis. Blood 87 4651–4663.

    Not in our library

  175. 175.

    Sims P. J. Wiedmer T. Esmon C. T. Weiss H. J. Shattil S. J. (1989 ). Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet procoagulant activity. J. Biol. Chem. 264 17049–17057.

    Not in our library

  176. 176.

    Sinauridze E. I. Kireev D. A. Popenko N. Y. Pichugin A. V. Panteleev M. A. Krymskaya O. V. (2007 ). Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets. Thromb. Haemost. 97 425–434.

    Not in our library

  177. 177.

    Skeppholm M. Mobarrez F. Malmqvist K. Wallen H. (2012 ). Platelet-derived microparticles during and after acute coronary syndrome. Thromb. Haemost. 107 1122–1129.

    Not in our library10.1160/th11-11-0779

  178. 178.

    Sommeijer D. W. Joop K. Leyte A. Reitsma P. H. ten Cate H. (2005 ). Pravastatin reduces fibrinogen receptor gpIIIa on platelet-derived microparticles in patients with type 2 diabetes. J. Thromb. Haemost. 3 1168–1171.

    Not in our library10.1111/j.1538-7836.2005.01403.x

  179. 179.

    Stahl A. L. Sartz L. Karpman D. (2011 ). Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Blood 117 5503–5513.

    Not in our library10.1182/blood-2010-09-309161

  180. 180.

    Suades R. Padro T. Alonso R. Lopez-Miranda J. Mata P. Badimon L. (2014 ). Circulating CD45+/CD3+ lymphocyte-derived microparticles map lipid-rich atherosclerotic plaques in FH patients. Thromb. Haemost. 111 111–121.

    Not in our library10.1160/th13-07-0612

  181. 181.

    Suades R. Padro T. Alonso R. Mata P. Badimon L. (2013 ). Lipid-lowering therapy with statins reduces microparticle shedding from endothelium, platelets and inflammatory cells indicating protection against cell activation. Thromb. Haemost. 110 366–377.

    Not in our library10.1160/th13-03-0238

  182. 182.

    Suades R. Padro T. Alonso R. Mata P. Badimon L. (2015a ). High levels of TSP1+/CD142+ platelet-derived microparticles characterise young patients with high cardiovascular risk and subclinical atherosclerosis. Thromb. Haemost. 114 1310–1321.

    Not in our library10.1160/th15-04-0325

  183. 183.

    Suades R. Padro T. Badimon L. (2015b ). The role of blood-borne microparticles in inflammation and hemostasis. Semin. Thromb. Hemost. 41 590–606.

    Not in our library10.1055/s-0035-1556591

  184. 184.

    Suades R. Padro T. Vilahur G. Martin-Yuste V. Sabate M. Sans-Rosello J. (2015c ). Growing thrombi release increased levels of CD235a(+) microparticles and decreased levels of activated platelet-derived microparticles. Validation in ST-elevation myocardial infarction patients. J. Thromb. Haemost. 13 1776–1786.

    Not in our library10.1111/jth.13065

  185. 185.

    Suades R. Padro T. Crespo J. Ramaiola I. Martin-Yuste V. Sabate M. (2016 ). Circulating microparticle signature in coronary and peripheral blood of ST elevation myocardial infarction patients in relation to pain-to-PCI elapsed time. Int. J. Cardiol. 202 378–387.

    Not in our library10.1016/j.ijcard.2015.09.011

  186. 186.

    Suades R. Padro T. Vilahur G. Badimon L. (2012 ). Circulating and platelet-derived microparticles in human blood enhance thrombosis on atherosclerotic plaques. Thromb. Haemost. 108 1208–1219.

    Not in our library10.1160/th12-07-0486

  187. 187.

    Takano K. Asazuma N. Satoh K. Yatomi Y. Ozaki Y. (2004 ). Collagen-induced generation of platelet-derived microparticles in whole blood is dependent on ADP released from red blood cells and calcium ions. Platelets 15 223–229.

    Not in our library10.1080/09537100410001682797

  188. 188.

    Tan K. T. Tayebjee M. H. Lynd C. Blann A. D. Lip G. Y. (2005 ). Platelet microparticles and soluble P selectin in peripheral artery disease: relationship to extent of disease and platelet activation markers. Ann. Med. 37 61–66.

    Not in our library10.1080/07853890410018943

  189. 189.

    Tan M. Yan H. B. Li J. N. Li W. K. Fu Y. Y. Chen W. (2016 ). Thrombin stimulated platelet-derived exosomes inhibit platelet-derived growth factor receptor-beta expression in vascular smooth muscle cells. Cell. Physiol. Biochem. 38 2348–2365.

    Not in our library10.1159/000445588

  190. 190.

    Tans G. Rosing J. Thomassen M. C. Heeb M. J. Zwaal R. F. Griffin J. H. (1991 ). Comparison of anticoagulant and procoagulant activities of stimulated platelets and platelet-derived microparticles. Blood 77 2641–2648.

    Not in our library

  191. 191.

    Tehrani S. Mobarrez F. Antovic A. Santesson P. Lins P. E. Adamson U. (2010 ). Atorvastatin has antithrombotic effects in patients with type 1 diabetes and dyslipidemia. Thromb. Res. 126 e225–e231.

    Not in our library10.1016/j.thromres.2010.05.023

  192. 192.

    Terrisse A. D. Puech N. Allart S. Gourdy P. Xuereb J. M. Payrastre B. (2010 ). Internalization of microparticles by endothelial cells promotes platelet/endothelial cell interaction under flow. J. Thromb. Haemost. 8 2810–2819.

    Not in our library10.1111/j.1538-7836.2010.04088.x

  193. 193.

    Toth B. Nikolajek K. Rank A. Nieuwland R. Lohse P. Pihusch V. (2007 ). Gender-specific and menstrual cycle dependent differences in circulating microparticles. Platelets 18 515–521.

    Not in our library10.1080/09537100701525843

  194. 194.

    Trzepizur W. Martinez M. C. Priou P. Andriantsitohaina R. Gagnadoux F. (2014 ). Microparticles and vascular dysfunction in obstructive sleep apnoea. Eur. Respir. J. 44 207–216.

    Not in our library10.1183/09031936.00197413

  195. 195.

    Tschuor C. Asmis L. M. Lenzlinger P. M. Tanner M. Harter L. Keel M. (2008 ). In vitro norepinephrine significantly activates isolated platelets from healthy volunteers and critically ill patients following severe traumatic brain injury. Crit. Care 12 R80

    Not in our library10.1186/cc6931

  196. 196.

    Ueba T. Haze T. Sugiyama M. Higuchi M. Asayama H. Karitani Y. (2008 ). Level, distribution and correlates of platelet-derived microparticles in healthy individuals with special reference to the metabolic syndrome. Thromb. Haemost. 100 280–285.

    Not in our library

  197. 197.

    Ueba T. Nomura S. Inami N. Nishikawa T. Kajiwara M. Iwata R. (2010 ). Plasma level of platelet-derived microparticles is associated with coronary heart disease risk score in healthy men. J. Atheroscler. Thromb. 17 342–349.

    Not in our library10.5551/jat.2964

  198. 198.

    van der Wal A. C. Becker A. E. (1999 ). Atherosclerotic plaque rupture–pathologic basis of plaque stability and instability. Cardiovasc. Res. 41 334–344.

    Not in our library10.1016/s0008-6363(98)00276-4

  199. 199.

    van der Wal A. C. Becker A. E. van der Loos C. M. Das P. K. (1994 ). Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 89 36–44.

    Not in our library10.1161/01.cir.89.1.36

  200. 200.

    van der Zee P. M. Biro E. Ko Y. de Winter R. J. Hack C. E. Sturk A. (2006 ). P-selectin- and CD63-exposing platelet microparticles reflect platelet activation in peripheral arterial disease and myocardial infarction. Clin. Chem. 52 657–664.

    Not in our library10.1373/clinchem.2005.057414

  201. 201.

    van Nispen tot Pannerden H. de Haas F. Geerts W. Posthuma G. van Dijk S. Heijnen H. F. (2010 ). The platelet interior revisited: electron tomography reveals tubular alpha-granule subtypes. Blood 116 1147–1156.

    Not in our library10.1182/blood-2010-02-268680

  202. 202.

    VanWijk M. J. VanBavel E. Sturk A. Nieuwland R. (2003 ). Microparticles in cardiovascular diseases. Cardiovasc. Res. 59 277–287.

    Not in our library10.1016/s0008-6363(03)00367-5

  203. 203.

    Varon D. Hayon Y. Dashevsky O. Shai E. (2012 ). Involvement of platelet derived microparticles in tumor metastasis and tissue regeneration. Thromb. Res. 130(Suppl. 1), S98–S99.

    Not in our library10.1016/j.thromres.2012.08.289

  204. 204.

    Vasina E. M. Cauwenberghs S. Feijge M. A. Heemskerk J. W. Weber C. Koenen R. R. (2011 ). Microparticles from apoptotic platelets promote resident macrophage differentiation. Cell Death Dis. 2 e211

    Not in our library10.1038/cddis.2011.94

  205. 205.

    Vasina E. M. Cauwenberghs S. Staudt M. Feijge M. A. Weber C. Koenen R. R. (2013 ). Aging- and activation-induced platelet microparticles suppress apoptosis in monocytic cells and differentially signal to proinflammatory mediator release. Am. J. Blood Res. 3 107–123.

    Not in our library

  206. 206.

    von Hundelshausen P. Weber C. (2007 ). Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ. Res. 100 27–40.

    Not in our library10.1161/01.res.0000252802.25497.b7

  207. 207.

    Weber A. Koppen H. O. Schror K. (2000 ). Platelet-derived microparticles stimulate coronary artery smooth muscle cell mitogenesis by a PDGF-independent mechanism. Thromb. Res. 98 461–466.

    Not in our library10.1016/s0049-3848(00)00192-4

  208. 208.

    Wickman G. R. Julian L. Mardilovich K. Schumacher S. Munro J. Rath N. (2013 ). Blebs produced by actin-myosin contraction during apoptosis release damage-associated molecular pattern proteins before secondary necrosis occurs. Cell Death Differ. 20 1293–1305.

    Not in our library10.1038/cdd.2013.69

  209. 209.

    Wiedmer T. Shattil S. J. Cunningham M. Sims P. J. (1990 ). Role of calcium and calpain in complement-induced vesiculation of the platelet plasma membrane and in the exposure of the platelet factor Va receptor. Biochemistry 29 623–632.

    Not in our library10.1021/bi00455a005

  210. 210.

    Willis G. R. Connolly K. Ladell K. Davies T. S. Guschina I. A. Ramji D. (2014 ). Young women with polycystic ovary syndrome have raised levels of circulating annexin V-positive platelet microparticles. Hum. Reprod. 29 2756–2763.

    Not in our library10.1093/humrep/deu281

  211. 211.

    Windelov N. A. Johansson P. I. Sorensen A. M. Perner A. Wanscher M. Larsen C. F. (2014 ). Low level of procoagulant platelet microparticles is associated with impaired coagulation and transfusion requirements in trauma patients. J. Trauma Acute Care Surg. 77 692–700.

    Not in our library10.1097/ta.0000000000000437

  212. 212.

    Xiao H. Jepkorir C. J. Harvey K. Remick D. G. (2002 ). Thrombin-induced platelet microparticles improved the aggregability of cryopreserved platelets. Cryobiology 44 179–188.

    Not in our library10.1016/s0011-2240(02)00024-x

  213. 213.

    Xie R. F. Hu P. Wang Z. C. Yang J. Yang Y. M. Gao L. (2015 ). Platelet-derived microparticles induce polymorphonuclear leukocyte-mediated damage of human pulmonary microvascular endothelial cells. Transfusion 55 1051–1057.

    Not in our library10.1111/trf.12952

  214. 214.

    Yano Y. Kambayashi J. Shiba E. Sakon M. Oiki E. Fukuda K. (1994 ). The role of protein phosphorylation and cytoskeletal reorganization in microparticle formation from the platelet plasma membrane. Biochem. J. 299(Pt. 1), 303–308.

    Not in our library10.1042/bj2990303

  215. 215.

    Zhang X. McGeoch S. C. Johnstone A. M. Holtrop G. Sneddon A. A. Macrury S. M. (2013 ). Platelet-derived microparticle count and surface molecule expression differ between subjects with and without type 2 diabetes, independently of obesity status. J. Thromb. Thrombolysis 37 455–463.

    Not in our library10.1007/s11239-013-1000-2

Cited by papers we hold 2

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.